AKUMSNSEAKUMS DRUGS AND PHARMA LHighPositive
Announced Thu, 23 Jul · 23:15 IST

Akums subsidiary to acquire Oriflame India manufacturing business for Rs 56 Cr

Listed Co AcquisitionStrategic Transactions View source PDFExplain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.4%1-day move
₹692.00
prior close
₹688.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1-0.9-0.5-0.4-2.4-4.3-3.9-4.8-4.8-3.4+4.7
Up moveDown movePending
AI summary

Akums Drugs' wholly-owned subsidiary Pure and Cure Healthcare will acquire Oriflame India's manufacturing business for Rs 56 Crore in cash. The deal includes two plants in Roorkee (Uttarakhand) and Noida (UP), plus a Noida warehouse. Trademark and marketing rights are excluded. The move marks Akums' entry into color cosmetics and expands its skincare and wellness capabilities. Expected to close by August 31, 2026. No related party issues or regulatory approvals needed.

Likely market impact

Expands manufacturing capacity and enters color cosmetics segment. Modest deal size at Rs 56 Cr suggests limited near-term earnings impact, but opens a new growth avenue.